|
|||||
|
|
BRAF‐Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location,Reticulin Fiber Deposition and CD34 Expression |
|
| Authors: | Christian Koelsche Felix Sahm Adelheid Wöhrer Astrid Jeibmann Jens Schittenhelm Patricia Kohlhof Matthias Preusser Bernd Romeike Hildegard Dohmen‐Scheufler Christian Hartmann Michel Mittelbronn Albert Becker Andreas von Deimling David Capper |
| Institution: | 1. Department of Neuropathology, Ruprecht‐Karls‐Universit?t Heidelberg, , Heidelberg, Germany;2. German Cancer Consortium (DKTK), CCU Neuropathology, German Cancer Research Center (DKFZ), , Heidelberg, Germany;3. Institute of Neurology, Medical University of Vienna, , Vienna, Austria;4. Institute of Neuropathology, University Hospital Münster, , Münster, Germany;5. Department of Neuropathology, Institute for Pathology and Neuropathology, University of Tübingen, , Tübingen, Germany;6. Department of Pathology, Klinikum Stuttgart, Katharinenhospital, , Stuttgart, Germany;7. Comprehensive Cancer Center, Medical University of Vienna, , Vienna, Austria;8. Department of Medicine I, Medical University of Vienna, , Vienna, Austria;9. Institute of Pathology, Department of Neuropathology, Jena University Hospital, Friedrich Schiller University, , Jena, Germany;10. Institute of Neuropathology, Medical School, Justus Liebig University, , Giessen, Germany;11. Department for Neuropathology, Hannover Medical School, , Hanover, Germany;12. Neurological Institute (Edinger‐Institut), Goethe University, , Frankfurt am Main, Germany;13. German Cancer Consortium (DKTK), , Heidelberg, Germany;14. German Cancer Research Center (DKFZ), , Heidelberg, Germany;15. Department of Neuropathology, University of Bonn, , Bonn, Germany |
| Abstract: | BRAF V600E mutation and homozygous deletion of CDKN2A (p16) are frequent molecular alterations in pleomorphic xanthoastrocytomas (PXAs). We investigated 49 PXAs for clinical, histological and immunohistochemical characteristics related to BRAF mutation status. BRAF mutation was detected by immunohistochemical assay and DNA sequencing in 38/49 (78%) tumors. All but one PXA located in the temporal lobe harbored a BRAF V600E mutation (23/24; 96%) compared with 10/19 nontemporal PXAs (53%; P = 0.0009). Histological and immunohistochemical analysis demonstrated increased reticulin deposition (76% vs. 27%; P = 0.003) and a more frequent expression of CD34 in BRAF‐mutant PXAs (76% vs. 27%; P = 0.003). We further investigated the utility of combined BRAF V600E (VE1) and p16 analysis by immunohistochemistry to distinguish PXAs from relevant histological mimics like giant‐cell glioblastoma. Among PXAs, 38/49 (78%) were VE1‐positive, and 30/49 (61%) had a loss of p16 expression. The combined features (VE1 positivity/p16 loss) were observed in 25/49 PXAs (51%) but were not observed in giant‐cell glioblastoma (VE1 0/28, p16 loss 14/28). We demonstrate that temporal location, reticulin deposition and CD34 expression are associated with BRAF mutation in PXA. Combined VE1 positivity and p16 loss represents a frequent immunoprofile of PXA and may therefore constitute an additional diagnostic tool for its differential diagnosis. |
| Keywords: | brain tumor BRAF V600E CDKN2A CD34 immunohistochemistry pleomorphic xanthoastrocytoma p16 VE1 |